Twelve weeks of ombitasvir/paritaprevir/r and dasabuvir without ribavirin is effective and safe in the treatment of patients with HCV genotype 1b infection and compensated cirrhosis: results from a real-world cohort study

  1. Chamorro-de-Vega, E.
  2. Gimenez-Manzorro, A.
  3. Rodriguez-Gonzalez, C.-G.
  4. Escudero-Vilaplana, V.
  5. De Lorenzo-Pinto, A.
  6. Iglesias-Peinado, I.
  7. Herranz-Alonso, A.
  8. Sanjurjo Saez, M.
Revista:
Expert Opinion on Drug Safety

ISSN: 1744-764X 1474-0338

Año de publicación: 2018

Volumen: 17

Número: 3

Páginas: 235-241

Tipo: Artículo

DOI: 10.1080/14740338.2018.1424829 GOOGLE SCHOLAR